Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AMAG Pharmaceuticals Inc (NASDAQ:AMAG)

64.95
Delayed Data
As of Jul 29
 -1.28 / -1.93%
Today’s Change
18.04
Today|||52-Week Range
77.73
+52.39%
Year-to-Date
Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog
Jul 29 / Zacks.com
Gilead (GILD) Presents Encouraging Data on HIV Candidate - Analyst Blog
Jul 22 / Zacks.com
Cytori Therapeutics (CYTX) Jumps: Stock Moves Up 10% - Tale of the Tape
Jul 29 / Zacks.com
Illumina Tops Q2 Earnings, Misses on Revenues; EPS View Up - Analyst Blog
Jul 22 / Zacks.com
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
Jul 28 / Zacks.com
Should You Buy AMAG Pharmaceuticals (AMAG) Ahead of Earnings? - Tale of the Tape
Jul 22 / Zacks.com
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 9.5% - Tale of the Tape
Jul 28 / Zacks.com
Exelixis Meteoric Rise on Positive Kidney Cancer Study Data - Analyst Blog
Jul 21 / Zacks.com
Trade-Ideas: AMAG Pharmaceuticals (AMAG) Is Today's "Water-Logged And Getting Wetter"...
Jul 27 / TheStreet.com
Will Currency and Generics Hit Eli Lilly's Q2 Earnings? - Analyst Blog
Jul 21 / Zacks.com
Is PerkinElmer (PKI) Poised to Beat Q2 Earnings Estimates? - Analyst Blog
Jul 27 / Zacks.com
Horizon Pharma Up on Expected Q2 Sales, 2015 Outlook - Analyst Blog
Jul 21 / Zacks.com
Will Varian Medical's (VAR) Q3 Earnings Impress Investors? - Analyst Blog
Jul 27 / Zacks.com
BioMarin Provides Update on Phase II Talazoparib Study - Analyst Blog
Jul 21 / Zacks.com
Cara Therapeutics (CARA) Jumps: Stock Moves Up 7.6% - Tale of the Tape
Jul 27 / Zacks.com
Bristol-Myers' Opdivo Study Stopped Early, Meets Endpoint - Analyst Blog
Jul 21 / Zacks.com
Biogen Tops Q2 Earnings, Cuts View on Tecfidera Issues - Analyst Blog
Jul 24 / Zacks.com
Anthera Pharmaceuticals (ANTH) Looks Good: Stock Up 13% - Tale of the Tape
Jul 21 / Zacks.com
AbbVie Tops Earnings, Misses on Revenues, Maintains View - Analyst Blog
Jul 24 / Zacks.com
AbbVie Neurodegenerative Disorder Drug Gets Orphan Status - Analyst Blog
Jul 20 / Zacks.com
XOMA Crashes after Gevokizumab Misses Primary Endpoint - Analyst Blog
Jul 23 / Zacks.com
Can C.R. Bard (BCR) Surprise Earnings Estimates in Q2? - Analyst Blog
Jul 20 / Zacks.com
Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog
Jul 23 / Zacks.com
Baxalta & Nektar Reveal Full Data from Hemophilia Study - Analyst Blog
Jul 17 / Zacks.com
Perrigo (PRGO) to Buy Yokebe Brand; Boost EU Presence - Analyst Blog
Jul 23 / Zacks.com
Hospira (HSP) Launches Generic Angiomax in the U.S. - Analyst Blog
Jul 17 / Zacks.com
Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog
Jul 23 / Zacks.com
Amgen Reports Positive Data on Leukemia Drug Blincyto - Analyst Blog
Jul 17 / Zacks.com
Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog
Jul 23 / Zacks.com
AstraZeneca Strikes Deal to Market Benralizumab in Japan - Analyst Blog
Jul 17 / Zacks.com
Celgene Q2 Earnings & Revenues In Line, Keeps View - Analyst Blog
Jul 23 / Zacks.com
Asterias Biotherapeutics (AST) Looks Good: Stock Up 13.4% - Tale of the Tape
Jul 17 / Zacks.com
Eli Lilly Beats on 2Q Earnings by Wide Margin, Ups View - Analyst Blog
Jul 23 / Zacks.com
Ohr Pharmaceutical Jumps on Positive Eye Drug Study Data - Analyst Blog
Jul 16 / Zacks.com
Amgen's Repatha Gains EU Nod; First PCSK9 Drug Approved - Analyst Blog
Jul 22 / Zacks.com
Sanofi Unveils Restructuring Plans, Prunes Business Units - Analyst Blog
Jul 16 / Zacks.com
Bristol-Myers' HIV-1 Inhibitor Gets Breakthrough Designation - Analyst Blog
Jul 22 / Zacks.com
Novartis' Malaria Drug Gets WHO Nod for Public Procurement - Analyst Blog
Jul 16 / Zacks.com
Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog
Jul 22 / Zacks.com
Cara Therapeutics (CARA) Jumps: Stock Moves Up 7.3% - Tale of the Tape
Jul 16 / Zacks.com